Announcements Trials
Browse Landscape

Phase

Phase 2 5Phase 1/2 2Phase 1 2Phase NA 1Phase 3 1

Status

Completed 2

Sponsor Class

NIH 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gynecologic 1Genitourinary 1Gastrointestinal 1Breast 1

Conditions

Melanoma 7Breast Neoplasms 6Colorectal Neoplasms 4Ovarian Neoplasms 3Neuroblastoma 3Neoplasm Metastasis 3Uveal Melanoma 2Unspecified Adult Solid Tumor, Protocol Specific 2Triple Negative Breast Neoplasms 2Prostatic Neoplasms 2Neoplasms 2Multiple Myeloma 2Lymphoma 2Lung Neoplasms 2Endometrial Neoplasms 2Carcinoma, Renal Cell 2Carcinoma, Non-Small-Cell Lung 2Breast Neoplasms, Male 2Adenocarcinoma 2Wilms Tumor 1Waldenstrom Macroglobulinemia 1Uterine Cervical Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Small Cell Lung Carcinoma 1Skin Neoplasms 1Rectal Neoplasms 1Pancreatic Neoplasms 1Neoplasms, Plasma Cell 1Lymphoma, Non-Hodgkin 1Lymphoma, Mantle-Cell 1

Interventions

pembrolizumab 44Nivolumab 29Gemcitabine 28Paclitaxel 19Cisplatin 18Ipilimumab 15Carboplatin 14Cyclophosphamide 13Capecitabine 12Dexamethasone 10Bevacizumab 10cemiplimab 9Irinotecan 9Docetaxel 9Albumin-Bound Paclitaxel 9130-nm albumin-bound paclitaxel 9spartalizumab 8Pemetrexed 8Sorafenib 7Rituximab 7Cetuximab 7fludarabine 6Temozolomide 6Taxes 6Radiotherapy 6Leucovorin 6Fluorouracil 6Azacitidine 6Ascorbic Acid 6lenvatinib 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × Neoplasms × sargramostim × Clear all
NCT01784913 2024-12-16

UV1/hTERT2012P

Ultimovacs ASA

Phase 1/2 Completed
22 enrolled
Genitourinary

Neoplasms, Prostatic Neoplasms

NCT00088413 2019-04-16

PANVAC-V and PANVAC-F Vaccines Plus Sargramostim to Treat Advanced Cancer

National Institutes of Health Clinical Center (CC)

Phase 1/2 Completed
51 enrolled 20 charts
BreastGastrointestinalGynecologic

Adenocarcinoma, Breast Neoplasms, Neoplasms, Ovarian Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡